Julie Smith
Directeur/Membre du Conseil chez EXELIXIS, INC.
Fortune : 335 327 $ au 31/05/2024
Profil
Julie Anne Smith is currently the Chief Executive Officer & Director at Nuvig Therapeutics, Inc., the Independent Director at Exelixis, Inc., and the Independent Director at Stoke Therapeutics, Inc. She previously held positions as the President, Chief Executive Officer & Director at Horizon Pharmaceutical LLC, the President & Chief Executive Officer at Raptor Pharmaceuticals, Inc., the President, Chief Executive Officer & Director at Nuredis, Inc., the President, Chief Executive Officer & Director at ESCAPE Bio, Inc., the Director-Channel Strategy & Design at Bristol Myers Squibb Co., the Director-Health & Emerging Companies Sections at Biotechnology Innovation Organization, the Independent Director at Astellas Gene Therapies, Inc., the Vice President-Commercial at Jazz Pharmaceuticals, Inc., the Vice President-Global Marketing at Genzyme General, the Head-Operations & Business Development at Novazyme Pharmaceuticals, Inc., and the Chief Commercial Officer & Vice President at Enobia Pharma, Inc. She obtained her undergraduate degree from Cornell University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EXELIXIS, INC.
0,01% | 31/05/2024 | 15 460 ( 0,01% ) | 335 327 $ | 31/05/2024 |
STOKE THERAPEUTICS, INC.
-.--% | 05/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Julie Smith
| Sociétés | Poste | Début |
|---|---|---|
| EXELIXIS, INC. | Directeur/Membre du Conseil | 22/09/2016 |
| STOKE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 04/06/2020 |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Directeur Général | 04/01/2023 |
Anciens postes connus de Julie Smith
| Sociétés | Poste | Fin |
|---|---|---|
ESCAPE Bio, Inc.
 ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | Directeur Général | 01/08/2022 |
| AUDENTES THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/01/2020 |
Nuredis, Inc.
 Nuredis, Inc. BiotechnologyHealth Technology Nuredis, Inc. develops treatments for neurodegenerative and neuromuscular diseases. The private company is based in Menlo Park, CA. The company was founded by Stanley N. Cohen. | Directeur Général | 01/06/2018 |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Directeur Général | 01/10/2016 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/05/2012 |
Formation de Julie Smith
| Cornell University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| EXELIXIS, INC. | Health Technology |
| STOKE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
Jazz Pharmaceuticals, Inc.
 Jazz Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA. | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Genzyme General
 Genzyme General Medical SpecialtiesHealth Technology Part of Sanofi, Genzyme General develops and markets specialty therapeutic, surgical, and diagnostic products. The company is based in Cambridge, MA. | Health Technology |
Novazyme Pharmaceuticals, Inc.
 Novazyme Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK. | Commercial Services |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | Health Technology |
Nuredis, Inc.
Nuredis, Inc. BiotechnologyHealth Technology Nuredis, Inc. develops treatments for neurodegenerative and neuromuscular diseases. The private company is based in Menlo Park, CA. The company was founded by Stanley N. Cohen. | Health Technology |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
